Sign In
Buy ASMB
$24.57
+0.0800 (+0.327%)
At Close: Jun 03, 2026
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 05'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript
04:57pm, Sunday, 28'th Feb 2021
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript
Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
06:41am, Friday, 26'th Feb 2021
Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B the
Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates
07:44pm, Thursday, 25'th Feb 2021
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
04:00pm, Thursday, 25'th Feb 2021
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel t
Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know
01:39pm, Wednesday, 24'th Feb 2021
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 05'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences to Wind-Down Microbiome Program
04:02pm, Tuesday, 08'th Dec 2020
Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
08:00am, Tuesday, 17'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV preg e n o mic ( pg ) RNA as a key biomarker , as well as highlight Assembly Bio's core inhibitor clinica
Why Assembly Biosciences Stock Crashed Today
04:41pm, Friday, 06'th Nov 2020
The clinical-stage biotech had a big pipeline setback.
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences News: Why ASMB Stock Is Plunging 68% Today
12:03pm, Friday, 06'th Nov 2020
Assembly Biosciences (ASMB) news for Friday includes clinical trial information from its third quarter of 2020 dropping ASMB stock. The post Assembly Biosciences News: Why ASMB Stock Is Plunging 68% T
